Dr. Yilong Wang: Executive Vice President, Professor of Neuroscience, Chief Physician at Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Dr. Yilong Wang, a distinguished neurologist and academic leader, serves as the Executive Vice President and Chief Physician at Beijing Tiantan Hospital, Capital Medical University. His expertise lies in cerebrovascular diseases and rare neurological disorders, with a particular focus on precision treatment strategies and innovative drug delivery systems. With extensive academic experience, including a postdoctoral fellowship at the University of California, he has made substantial contributions to stroke and small vessel disease research.
Online Profiles
Dr. Wang’s online presence is marked by his significant contributions to neuroscience and stroke research. He holds leadership roles in several academic societies, including the Chinese Stroke Association and the Chinese Medical Association. His research, particularly in stroke prevention and treatment, has gained international attention, with multiple publications in top-tier journals like NEJM and JAMA. He also serves as an editorial board member for Stroke & Vascular Neurology and the Chinese Stroke Journal.
Education
Dr. Wang’s academic foundation includes a Ph.D. in Neurology from Capital Medical University, complemented by a Master’s in Epidemiology and Health Statistics from North China Coal Medical College. He further honed his expertise through a postdoctoral fellowship in Neurology at the University of California, San Francisco, School of Medicine, from 2007 to 2009, where he expanded his research into cerebrovascular and neurological diseases.
Research Focus
Dr. Wang’s research focuses on cerebrovascular diseases, particularly ischemic stroke, and rare neurological disorders. His work explores precision diagnostic technologies, stroke prevention, and novel drug delivery methods that bypass the blood-brain barrier. His interdisciplinary research also involves medical-engineering crossover innovations, including intelligent medical devices and brain-computer interfaces, to improve neurological disease management and outcomes.
Experience
Dr. Wang’s professional trajectory spans various leadership positions at Beijing Tiantan Hospital, including Executive Vice President, Vice President, and Deputy Director of the Neurology Center. He has also held significant roles in the hospital’s scientific and technological departments, contributing to advancements in medical research, clinical practices, and technology integration for cerebrovascular diseases.
Research Timeline
Dr. Wang’s research has been supported by numerous national and international grants. His key projects include studies on precision treatment strategies for acute ischemic stroke and cerebral small vessel diseases. From 2019 to 2023, he led the National Natural Science Foundation of China’s Outstanding Youth Science Fund project, contributing to groundbreaking work on ischemic stroke therapies and intervention techniques. His ongoing research addresses innovative drug delivery systems and vascular disease treatment strategies.
Awards & Honors
Dr. Wang has earned numerous prestigious awards, including the National “Ten Thousand Talents Plan” Leading Talent in Science and Technology Innovation and the Young Scholar award from the Chang Jiang Scholars Program. He has also been recognized with various science and technology progress awards, both nationally and internationally, for his contributions to cerebrovascular disease research and innovations in medical technology.
Top-Noted Publication
Dr. Wang’s landmark publications include his recent work in NEJM (2023), where he introduced a dual-target intensive antiplatelet therapy for mild strokes, significantly impacting clinical treatment approaches. Another key publication in JAMA Neurology (2024) explored the role of statin therapy in neuroprotection during acute ischemic stroke, establishing him as a leader in stroke research. His work continues to shape medical guidelines for stroke prevention and treatment worldwide.
- Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack
Published in JAMA on July 5, 2016. This study explored the influence of CYP2C19 loss-of-function allele status on the effectiveness of clopidogrel, providing insights into personalized stroke prevention strategies.
DOI: 10.1001/jama.2016.8662 - Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial
Published in Circulation on July 7, 2015. This article discussed the results of the CHANCE trial, examining the combination of clopidogrel and aspirin in reducing the risk of stroke recurrence in patients with minor strokes or transient ischemic attacks.
DOI: 10.1161/circulationaha.114.014791 - Prevalence, Knowledge, and Treatment of Transient Ischemic Attacks in China
Published in Neurology on June 9, 2015. This study highlighted the prevalence and public awareness of transient ischemic attacks in China, along with the treatment approaches, contributing valuable data to the global understanding of stroke management in the region.
DOI: 10.1212/wnl.0000000000001665